Aims and Scope of Expert Review of Pharmacoeconomics and Outcomes Research
Expert Review of Pharmacoeconomics & Outcomes Research is a bimonthly peer-reviewed medical journal covering all aspects of pharmacoeconomics. It was established in 2001 and is published by Informa. The editor-in-chief is A. Bottomley (European Organisation for Research and Treatment of Cancer). Less
Key Metrics
CiteScore 

3.4
H-Index 

60
Impact Factor 

< 5
SJR 

Q2Health Policy

SNIP 

0.9
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Review of Pharmacoeconomics and Outcomes Research
Expert Review of Pharmacoeconomics and Outcomes Research Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Review of Pharmacoeconomics and Outcomes Research ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Review of Pharmacoeconomics and Outcomes Research
Estimating respiratory syncytial virus health utility values for older adults and their caregivers in the Japanese population: a time trade-off study
- 17 May 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Analyzing the direct medical cost of schizophrenia in Hospital Pulau Pinang, Malaysia
- 16 May 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005–2019
- 3 May 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB–IIC melanoma in the United States
- 26 Apr 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Cost and clinical analysis of community-acquired pneumonia within an antimicrobial stewardship-governed academic hospital in South Africa, and its implications
- 23 Apr 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Physicians’ preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China
- 21 Apr 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Estimating respiratory syncytial virus health utility values for older adults and their caregivers in the Japanese population: a time trade-off study
- 17 May 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Analyzing the direct medical cost of schizophrenia in Hospital Pulau Pinang, Malaysia
- 16 May 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
The relationship between changes in prescription drug sales and changes in mortality and hospital utilization in Denmark, 2005–2019
- 3 May 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB–IIC melanoma in the United States
- 26 Apr 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Cost and clinical analysis of community-acquired pneumonia within an antimicrobial stewardship-governed academic hospital in South Africa, and its implications
- 23 Apr 2026
- Expert Review of Pharmacoeconomics & Outcomes Research
Physicians’ preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in China
- 21 Apr 2026
- Expert Review of Pharmacoeconomics & Outcomes Research